Xencor, Inc. (XNCR) is a Biotechnology company in the Healthcare sector, currently trading at $12.51. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is XNCR = $29 (+129.8% upside).
Valuation: XNCR trades at a trailing Price-to-Earnings (P/E) of -9.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.03.
Financials: revenue is $126M, -6.1%/yr average growth. Net income is $92M (loss), growing at -50.8%/yr. Net profit margin is -73.2% (negative). Gross margin is 91.6% (-3.1 pp trend).
Balance sheet: total debt is $188M against $636M equity (Debt-to-Equity (D/E) ratio 0.3, conservative). Current ratio is 6.25 (strong liquidity). Debt-to-assets is 21.4%. Total assets: $875M.
Analyst outlook: 24 / 27 analysts rate XNCR as buy (89%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 88/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 55/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
